LB Pharmaceuticals to Participate in Upcoming March Investor Events

Core Viewpoint - LB Pharmaceuticals Inc is actively engaging with investors through upcoming conferences to discuss its late-stage development of novel therapies for neuropsychiatric diseases [1][2]. Group 1: Upcoming Conferences - The company will present at the Leerink 2026 Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET [1]. - The Stifel 2026 Virtual CNS Forum is scheduled for March 17, 2026, at 2:30 p.m. ET [2]. - Live webcasts of these presentations will be available on the company's website, with replays archived for future access [2]. Group 2: Company Overview - LB Pharmaceuticals is focused on developing therapies for schizophrenia, bipolar depression, and major depressive disorder, among other neuropsychiatric conditions [3]. - The lead product candidate, LB-102, is positioned to potentially be the first benzamide antipsychotic drug approved in the U.S. for neuropsychiatric disorders [3]. - If approved, LB-102 could become a key treatment option, offering a favorable clinical activity and tolerability profile compared to existing therapies [3].